SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Webhead who wrote (7487)10/16/1998 1:36:00 AM
From: aknahow  Read Replies (1) | Respond to of 17367
 
Thanks, would not have seen this without your post. Agree it is well written even though it may contain nothing new for us it should help others who might want to look further.

BTW I understand the Trauma P III trials now have over 400 accrued, and the Meningococcemia trial has 268.



To: Webhead who wrote (7487)10/16/1998 2:28:00 PM
From: BostonView  Read Replies (1) | Respond to of 17367
 
Thanks, Webhead. That's the most encouraging thing I've read about XOMA in a long time. I just wish it came from some (any) other source.

Any port in a storm, I guess.

BV



To: Webhead who wrote (7487)10/16/1998 3:56:00 PM
From: aknahow  Read Replies (1) | Respond to of 17367
 
Serious stuff on resistance from U.K. forum:

phls.co.uk



To: Webhead who wrote (7487)10/17/1998 9:43:00 AM
From: Skeeter Bug  Respond to of 17367
 
xoma has 12 months of cash available. will they be able to generate revenue in that time frame? do they have any alliances that will provide cash? tia...


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News